15 terminated. 15 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 PLX-PAD - COVID, ARDS | Phase 2 | Terminated | Pluristem Ltd. | 23 | 2020-10-19 | 2024-08-29 |
| Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 PLX-PAD, Placebo - COVID, ARDS | Phase 2 | Terminated | Pluristem Ltd. | 66 | 2020-10-01 | 2024-08-30 |
| Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection Placebo, Ivermectin, Losartan - Cancer, COVID | Phase 2 | Terminated | Instituto do Cancer do Estado de São Paulo | 77 | 2020-07-23 | 2022-08-09 |
| Use of Convalescent Plasma for COVID-19 Convalescent Plasma - COVID | Phase 2 | Terminated | Northside Hospital, Inc. | 8 | 2020-07-14 | 2022-11-14 |
| Pegylated Interferon Lambda Treatment for COVID-19 Pegylated interferon lambda - COVID-19, COVID | Phase 2 | Terminated | Raymond Chung | 14 | 2020-06-22 | 2022-07-21 |
| hCT-MSCs for COVID19 ARDS Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo - COVID, Corona Virus Infection | Phase 1 / Phase 2 | Terminated | Joanne Kurtzberg, MD | 12 | 2020-06-18 | 2022-12-20 |
| A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 SNDX-6352, Placebo - Coronavirus, COVID | Phase 2 | Terminated | Syndax Pharmaceuticals | 1 | 2020-05-30 | 2022-07-22 |
| Colchicine in Patients With Mild and Severe Coronavirus Disease Colchicine, Placebo oral tablet - COVID | Phase 2 | Terminated | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 116 | 2020-05-27 | 2022-08-10 |
| PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer Pacritinib, Placebo - COVID19, COVID-19 | Phase 2 | Terminated | CTI BioPharma | 200 | 2020-05-22 | 2024-06-05 |
| Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 CONVALESCENT PLASMA - COVID, SARS-CoV 2 | Phase 2 | Terminated | Azienda Ospedaliero, Universitaria Pisana | 1 | 2020-05-01 | 2020-11-12 |
| Novel Agents for Treatment of High-risk COVID-19 Positive Patients Ivermectin, Camostat Mesilate, Artemesia annua - COVID, Sars-CoV2 | Phase 2 | Terminated | Susanne Arnold | 13 | 2020-05-01 | 2022-01-20 |
| Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID Chloroquine, Placebo oral tablet - COVID, Coronavirus Infection | Phase 2 | Terminated | Columbia University | 5 | 2020-04-21 | 2025-02-27 |
| Estrogen Patch for COVID-19 Symptoms Estradiol patch - COVID | Phase 2 | Terminated | Sharon Nachman | 2 | 2020-04-20 | 2021-11-26 |
| Convalescent Plasma vs. Standard Plasma for COVID-19 Convalescent Plasma, Standard Donor Plasma - COVID | Phase 1 / Phase 2 | Terminated | Stony Brook University | 82 | 2020-04-08 | 2021-12-06 |
Coronavirus Infections (6) · COVID-19 (5) · Cytokine Release Syndrome (2) · Respiratory Distress Syndrome (2) · Acute Lung Injury (1) · Dyspnea (1) · Inflammation (1) · Neoplasms (1) · Pneumonia (1)
Coronaviridae Infections (8) · Infections (8) · Nidovirales Infections (8) · RNA Virus Infections (8) · Virus Diseases (8) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Pneumonia, Viral (5) · Respiratory Tract Infections (5) · Pneumonia (4) · Pathological Conditions, Signs and Symptoms (3) · Coronavirus Infections (2) · Pathologic Processes (2) · Respiration Disorders (2) · Shock (2)
Ivermectin (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Artesunate (1) · Chloroquine (1) · Colchicine (1) · Janus Kinase Inhibitors (1) · Losartan (1) · Ortho Evra (1) · aviptadil (1) · axatilimab (1) · camostat (1)
Pluristem Ltd. (2) · APR Applied Pharma Research s.a. (1) · Azienda Ospedaliero, Universitaria Pisana (1) · CTI BioPharma (1) · Columbia University (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Instituto do Cancer do Estado de São Paulo (1) · Joanne Kurtzberg, MD (1) · Northside Hospital, Inc. (1) · Raymond Chung (1) · Sharon Nachman (1) · Stony Brook University (1) · Susanne Arnold (1) · Syndax Pharmaceuticals (1)
United States (11) · Brazil (1) · Germany (1) · Israel (1) · Italy (1) · Mexico (1)
Anca Askanase, MD, MPH (1) · Elliott Bennett-Guerrero, MD (1) · Francesco Menichetti (1) · Joanne Kurtzberg, MD (1) · Jonathan C Javitt, MD, MPH (1) · Kent Holland, MD (1) · Lingye Chen, MD (1) · Maria del Pilar Diz, MD, PhD (1) · Pedro Exman, MD (1) · Raymond Chung, MD (1) · Sharon Nachman, MD (1) · Susanne Arnold, MD (1)
PMID 32219428, PMID 32788708, PMID 33240091, PMID 33870923, PMID 34013969, PMID 34473343, PMID 34755269, PMID 36469321, PMID 36734509, PMID 37162745